Ventyx Biosciences Inc VTYX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VTYX is a good fit for your portfolio.
News
-
The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx Biosciences
-
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)
-
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTYX
-
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm
-
VTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud Lawsuit
-
VTYX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action – VTYX
Trading Information
- Previous Close Price
- $4.06
- Day Range
- $3.93–4.08
- 52-Week Range
- $1.87–40.58
- Bid/Ask
- $3.89 / $3.94
- Market Cap
- $277.06 Mil
- Volume/Avg
- 529,730 / 4.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 80
- Website
- https://www.ventyxbio.com
Comparables
Valuation
|
Metric
|
VTYX
|
ARVN
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.03 | 3.26 | 2.95 |
Price/Sales | — | 22.34 | 1,835.80 |
Price/Cash Flow | — | — | — |
Price/Earnings
VTYX
ARVN
VRDN
Financial Strength
|
Metric
|
VTYX
|
ARVN
|
VRDN
|
|---|---|---|---|
Quick Ratio | 11.33 | 4.93 | 17.93 |
Current Ratio | 11.87 | 4.98 | 18.26 |
Interest Coverage | — | — | −137.76 |
Quick Ratio
VTYX
ARVN
VRDN
Profitability
|
Metric
|
VTYX
|
ARVN
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | −48.02% | −26.31% | −42.76% |
Return on Equity (Normalized) | −51.90% | −58.35% | −82.42% |
Return on Invested Capital (Normalized) | −55.64% | −63.59% | −50.70% |
Return on Assets
VTYX
ARVN
VRDN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zsdgtdcth | Fmlq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qwbmmqs | Sksbgb | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xvlqfvbg | Gmmcmbd | $97.8 Bil | |
MRNA
| Moderna Inc | Rmzxwwrms | Kblcb | $41.3 Bil | |
ARGX
| argenx SE ADR | Swmlzzclp | Ndcy | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Lvycmdf | Mxyt | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rcyqdxny | Ljnknf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ygxkjcgh | Qsdtj | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tdknrlcj | Lzdlblj | $12.5 Bil | |
INCY
| Incyte Corp | Lqwtxqr | Gmbvr | $11.6 Bil |